Abstract
PurposeBone metastasis from endometrial cancer (EC) is rare and poorly described. The purpose of the present study was to investigate the correlation between the clinically accessible factors and survival time among EC patients with bone metastasis.Patients and MethodsWe retrospectively identified and reviewed EC patients with bone metastasis from 2010 to 2016, based on the Surveillance, Epidemiology and End Results (SEER) database. Univariable and multivariable Cox regressions were applied to evaluate the effects of clinical variables on survival. Kaplan–Meier plots were used to visually demonstrate the correlation between independent risk factors and survival.ResultsClinical data of 584 EC patients with bone metastasis from the SEER database were analyzed. EC patients with bone metastasis experienced extremely poor survival, with 1-year overall survival (OS) and cancer-specific survival (CSS) rates 33.8 and 35.8%, respectively. Variables associated with OS and CSS in the univariable analysis included race, tumor grade, tumor subtype, tumor size, lung, liver and brain metastases, surgery, radiotherapy, and chemotherapy. In the multivariable analysis, tumor grade, tumor subtype, liver and brain metastases, local surgery, and systemic chemotherapy remained independent risk factors for OS and CSS. However, local radiotherapy was an independent predictor of OS, not CSS.ConclusionsWe identified several factors affect the survival of EC patients with bone metastasis, which is useful for clinicians to assess patients’ outcomes. Our study supports surgery and radiotherapy of primary EC, and systemic chemotherapy for prolonging survival among EC patients with bone metastasis, which lays a solid foundation for defining optimal treatment strategy in this specific cohort.
Highlights
As the most common malignancy of female endometrium, endometrial cancer (EC) incidence rate has been rapidly rising in recent years [1, 2]
Lung metastasis accounted for 46.2%, liver metastasis accounted for 23.8%, and brain metastasis accounted for 7.2%
Our analysis found that lung was the most common metastatic organ (46.2%) in EC patients with bone metastasis, compared with other metastatic organs
Summary
As the most common malignancy of female endometrium, endometrial cancer (EC) incidence rate has been rapidly rising in recent years [1, 2]. With the rapid development of imaging techniques and treatment of EC, the incidence of bone metastasis is increasing. Bone metastasis is relatively uncommon in EC, with an incidence 0.6% [3]. Among patients in stage IV EC, bone metastasis occurred in 6.8% of patients [4]. Distant organ metastasis usually predicts a poor prognosis [5]. 5-year overall survival (OS) of EC was estimated around 80% in patients without metastatic disease [1, 2], metastatic EC patients experienced extremely poor prognosis with 5-year OS less than 20% [3, 4]. Common treatment methods for EC include surgery, radiotherapy, as well as systemic therapies. The standard management of EC with bone metastasis is unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
